In a cohort of 249 breast cancer brain metastasis (BCBM) patients (all female; median age 46 years), molecular subtypes were distributed as follows: luminal (38.95%), HER2-positive (32.93%), and triple-negative (28.11%). This evidence concerns the gene ERBB2 and breast cancer.